|European Case Law Identifier:||ECLI:EP:BA:2017:T236912.20170317|
|Date of decision:||17 March 2017|
|Case number:||T 2369/12|
|IPC class:||A61K 39/02|
|Language of proceedings:||EN|
|Download and more information:||
|Title of application:||Vaccination of Young Animals against Lawsonia Intracellularis Infections|
|Applicant name:||Boehringer Ingelheim Vetmedica, Inc.|
|Relevant legal provisions:||
|Keywords:||Sufficiency of disclosure - (no)|
Summary of Facts and Submissions
I. Appeal was filed by the applicant against the decision of the examining division to refuse European patent application EP 07797730, with the title "Vaccination of Young Animals against Lawsonia Intracellularis Infections".
II. The examining division considered a main and four auxiliary requests. It used its discretion according to Rule 137(3) EPC not to admit the main and auxiliary requests 1 and 2 into the proceedings. The subject-matter of claims 1 and 8 of auxiliary request 3 was held to lack novelty, while that of claims 1 to 14 of auxiliary request 4 was found to be obvious
(Article 56 EPC). In addition claims 1 and 8 of auxiliary request 4 were held to relate to an invention that was not disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art (Article 83 EPC).
III. With the statement of grounds of appeal the appellant filed a main request and two auxiliary requests and submitted a document (Exhibit A) with the title "Efficacy of Enterisol® Ileitis administered to Lawsonia-positive pigs 1 to 6 days of age".
IV. The board issued a communication pursuant to
Article 15(1) RPBA, setting out its preliminary appreciation of substantive and legal matters concerning the appeal.
V. The appellant responded to the board's communication by letter and by the filing of a new main and auxiliary requests I to IV, replacing all previous requests.
VI. Claim 1 of the main request reads:
"1. The use of an L. intracellularis antigen for the preparation of a medicament for the vaccination of a mammal having maternally derived anti-L. intra-cellularis antibodies, wherein said mammal is to be vaccinated with an effective dose of said attenuated L. intracellularis bacteria at day 1 to 9 of age by oral drench".
Claim 1 of auxiliary request I reads:
"1. The use of attenuated L. intracellularis bacteria for the preparation of a medicament for the vaccination of a mammal against L. intracellularis infections having maternally derived anti-L. intracellularis antibodies, wherein said mammal is to be vaccinated with an effective dose of said attenuated L. intracellularis bacteria at day 1 to 9 of age by oral drench, and, wherein said mammal is a pig".
VII. Oral proceedings before the board were held on 17 March 2017. At the end of these proceedings the Chairwoman announced the decision of the board.
VIII. The appellant's arguments relevant to the decision can be summarised as follows:
Admission into the proceedings - Articles 12(4) and 13(1) RPBA
The main request and auxiliary requests I to IV were filed to expedite the prosecution of the case. The amendments made to the claims of the main request and auxiliary requests I to IV aimed to address the issues raised by the board in the communication according to Article 15(1) RPBA and should therefore be admitted into the proceedings.
Auxiliary request I - Claim 1
Disclosure of the invention - Article 83 EPC
The claimed subject-matter was the use of attenuated
L. intracellularis bacteria for the preparation of a medicament for the vaccination of 1 to 9 day old pigs having maternally derived anti-L. intracellularis antibodies against L. intracellularis infections. The medicament was to be administered by oral drench.
The invention was disclosed in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art. Example 1 demonstrated, in vitro, that colostrum and milk from sows and gilts contained antibodies specific for L. intracellularis. Example 2 showed that L. intracellularis specific antibodies were not effective in inactivating L. intracellularis during gastrointestinal passage. This taught the skilled person that a live L. intracellularis vaccine would not be negatively affected by the maternal immunity status of the pig.
The question of whether or not pigs as young as 1 to 9 days old could mount an effective immune response after vaccination with attenuated L. intracellularis bacteria was answered by Example 3, which demonstrated that the L. intracellularis vaccine was efficacious when administered to 1 day old, maternal antibody negative piglets.
It was established case law of the Boards of Appeal that the requirements for sufficient disclosure of the invention were met when at least the suitability of the product for the claimed treatment (claimed therapeutic application) was disclosed in the application. In contrast, it was not necessary for the results of clinical trials to be provided. Rather, it was sufficient that the patent application provided information making it plausible that the claimed compound had a direct effect or activity. Furthermore, once said suitability was available, then post-published evidence must be taken into account.
From Examples 2 and 3 the skilled person could conclude that it was plausible that the L. intracellularis vaccine would be efficacious when administered to young piglets that were anti-L. intracellularis antibody positive.
This conclusion was further supported by the data of Example 4 which demonstrated that vaccination with the L. intracellularis vaccine in the face of maternal immunity in pigs at 3 weeks of age was effective. Thus, Example 4 confirmed that there was no interference between the anti-L. intracellularis antibodies and the L. intracellularis vaccine.
In addition to the positive evidence in the application, there was no evidence on file that there were serious doubts substantiated by verifiable facts that the application lacked sufficient disclosure. Indeed, the post-published data contained in "Exhibit A", filed with the statement of grounds of appeal, showed that the vaccine as claimed, provided protection when administered to piglets (at 1 week of age) in the face of maternal immunity (i.e. in a piglet having anti-L. intracellularis antibodies).
The study showed that vaccinated piglets from sows with anti-Lawsonia antibodies (group 1) had improved overall lesion scores when compared to a challenge control (group 5) and had improved clinical symptoms compared to several groups.
Thus, in view of the experimental data provided by the patent application and by Exhibit A, it was plausible that vaccination with the L. intracellularis vaccine in the face of maternal immunity in young pigs would be effective.
IX. The appellant requested that the decision under appeal be set aside and that a patent be granted on the basis of the main request or on one of the auxiliary requests.
Reasons for the Decision
Admission into the proceedings - Articles 12(4) and 13(1) RPBA
1. By virtue of Article 12(4) RPBA, the board has the discretionary power to hold inadmissible facts, evidence or requests which were filed with the statement of grounds of appeal if they "could have been presented [...] in the first instance proceedings".
1.1 The main request was filed as auxiliary request I with the statement of grounds of appeal. Claim 1 relates to the use of an L. intracellularis antigen to treat a mammal having maternally derived anti-L. intra-cellularis antibodies wherein the mammal to be treated is 1 to 9 days old. None of the requests considered by the examining division related to this combination of features. The board therefore has to either give a first ruling on this issue or to remit the case to the examining division (cf. Case Law of the Boards of Appeal of the EPO, 8th edition 2016, IV.E.4.3).
1.2 The board exercises its power under Article 12(4) RPBA and does not admit the main request into the appeal proceedings.
Auxiliary requests I to IV
2. The board admitted auxiliary requests I to IV into the proceedings (Article 13(1) RPBA).
Auxiliary request I - Claim 1
Disclosure of the invention - Article 83 EPC
3. Article 83 EPC requires that the European patent application discloses the invention in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art. In the case of a therapeutic use, the application must disclose the suitability of the product to be manufactured for the claimed therapeutic application (see Case Law of the Boards of Appeal of the European Patent Office, 8th edition, II.C.6.2).
4. For the therapeutic use of claim 1, the application must disclose the suitability of the attenuated L. intracellularis bacteria for the vaccination (i.e. for inducing immunity) of 1 to 9 day old pigs against L. intracellularis infections, when administered by oral drench.
5. The appellant argued that the application disclosed the suitability of attenuated L. intracellularis bacteria for the vaccination of 1 to 9 day old pigs against L. intracellularis infections. In particular, Examples 2 and 3, taken alone, demonstrated the suitability of attenuated L. intracellularis bacteria for the vaccination of 1 to 9 day old pigs against L. intracellularis infections.
6. The board does not consider these arguments as persuasive in the face of the evidence of Exhibit A, submitted by the appellant with the statement of grounds of appeal (see points 7 to 8.5, below). The results contained in the application were either from in vitro or tissue culture assays (Examples 1 and 2) or, if they were generated through animal studies, relate to maternal antibody-negative piglets or piglets of 3 weeks of age (Examples 3 and 4, respectively). On the other hand, the evidence in Exhibit A derives from a clinical study representing an embodiment of the claimed subject-matter, i.e. it provides direct evidence of the suitability of attenuated L. intra-cellularis for the purpose claimed and is therefore given more weight than the results contained in the application.
7. The Exhibit provides the results of a study "conducted to evaluate Enterisol® Ileitis vaccine efficacy in suckling piglets derived from Lawsonia intracellularis exposed (group A) and negative sows (group B) and to determine if there was any maternal interference with vaccine efficacy against a virulent, pure culture L. intracellularis challenge" (see Exhibit A, page 1).
8. Piglets in groups A and B were further divided into subgroups 1 to 6 (see Tables 1 and 2 of the Exhibit). Piglets in subgroups 1 and 4 were vaccinated with a single dose of attenuated modified live
L. intracellularis (Enterisol® Ileitis) at 1 week of age. Piglets in groups 2, 3, 5 and 6 received a placebo. At 6 to 7 weeks of age, piglet groups 1, 2, 4 and 5 received a virulent, pure culture of L. intracellularis challenge, while groups 3 and 6 did not.
8.1 All piglet groups were humanely euthanised and evaluated for macroscopic (gross) and Lawsonia-specific microscopic lesion development at 3 weeks post challenge administration (9 to 10 weeks of age; supra).
8.2 Table 2 provides a summary of average gross lesion scores for the small and large intestines, with group 1 being the trial group (piglets from L. intracellularis exposed sows, vaccinated) and group 2 being the control group (piglets from L. intracellularis exposed sows, unvaccinated). It can be seen from the table that the trial group has significantly larger intestinal lesions than the control group.
8.3 Table 3 provides a summary of average microscopic lesion scores for the small, large and whole intestines, with group 1 being the trial (vaccinated) group and group 2 being the control (unvaccinated) group. Here too, the trial group has significantly larger intestinal lesions than the control group.
8.4 The appellant argued that, although Tables 2 and 3 of the study report showed that group 1 piglets (from Lawsonia positive sows, vaccinated and challenged) had greater gross average lesion scores than the unvaccinated challenge control (group 2), the data in Table 4 confirmed that the same group, had better daily clinical scores than the unvaccinated control group.
8.5 Table 4 does indeed show that group 1 piglets had fewer clinical symptoms of infection than those in the challenge control (group 2). However, given the significance of intestinal lesions as a symptom of infection and of the fact that two out of three measures of infection were significantly worsened in piglets from sows exposed to L. intracellularis bacteria in comparison to the non-vaccinated piglets from the same sows, the board must conclude that Exhibit A as a whole raises serious doubts as to the suitability of attenuated L. intracellularis bacteria for the vaccination of 1 to 9 day old pigs against L. intracellularis infections when administered by oral drench, which cannot be overcome by the results in the application, given their indirect nature (see point 6 above).
9. In view of the above, the board holds that the application does not disclose the invention of claim 1 in a manner sufficiently clear and complete for it to be carried out by a person skilled in the art.
Auxiliary requests II to IV
10. Claim 1 of all of these requests relates, at least in an embodiment, to the same subject-matter as claim 1 of auxiliary request I. Thus, the conclusion reached for claim 1 of auxiliary request I on the disclosure of the invention applies equally.
11. In view of the above considerations, none of the pending claim requests relates to an invention for which the application meets the requirements
Article 83 EPC.
For these reasons it is decided that:
The appeal is dismissed.